Dupixent (dupilumab) – What to Expect for Biosimilar Risk in 2029
| Issue | What It Means | Likely Impact in 2029 | How Companies/Stakeholders Can Mitigate |
|-------|---------------|-----------------------|----------------------------------------|
| Patent & exclusivity window | Dupixent’s key patents (US, EU, and worldwide) are set to expire between 2024‑2026 (with some extensions for formulation and indications). | The first approved biosimilar could appear around 2029, about 3‑5 years after patent expiry, giving the original developer (Regeneron/Sanofi) a “patent‑life extension” window for pricing and market share. | 1. Accelerated development: Use platform technology (e.g., cell line engineering) to shorten timelines.
2. Strategic licensing: Negotiate early “first‑to‑file” agreements or “first‑to‑market” deals. |
| Regulatory pathway | In the US, the FDA requires a comparability exercise (PK/PD, immunogenicity, clinical efficacy/safety). In the EU, the EMA’s biosimilar dossier must show similarity. | 2029 biosimilars must meet rigorous standards. Delays in regulatory approvals could shift launch dates, but the regulatory environment is stable, so risk is low‑to‑moderate. | 1. Parallel submissions: File in both regions simultaneously.
2. Early interaction: Engage FDA/EMA early through meetings/consultations. |
| Immunogenicity & safety | Biosimilars may differ in glycosylation or impurities, potentially affecting immunogenicity. | Early post‑marketing surveillance (pharmacovigilance) is essential. The risk of unexpected adverse events is low if the similarity assessment is thorough. | 1. Robust post‑marketing studies.
2. Real‑world evidence: Collect data from registries and electronic health records. |
| Clinical efficacy & patient acceptance | If a biosimilar shows slightly lower efficacy in a niche subpopulation (e.g., severe atopic dermatitis), clinicians may be hesitant to switch. | The risk that a biosimilar will be under‑used is moderate. Patient perceptions of “biologic” vs. “biosimilar” also play a role. | 1. Educational campaigns for prescribers and patients.
2. Switch studies to demonstrate equivalence. |
| Market competition & pricing | Competition can drive prices down, but payers may use “step therapy” (requiring a branded drug first). | The risk of reduced revenues for the originator is moderate‑high if biosimilars capture 20‑40 % of the market by 2029. | 1. Price‑matching strategies.
2. Differentiation: Offer additional services (e.g., patient support, delivery). |
| Strategic partnership & licensing | Biosimilar manufacturers often partner with larger pharma companies for global roll‑outs. | Failure to secure a global partner could delay entry. | 1. Secure a global partner early.
2. Joint‑venture with a pay‑or‑win model. |
| Patent litigation & secondary patents | The originator can file secondary patents (formulation, delivery device) to extend exclusivity. | Legal disputes may delay biosimilar entry. | 1. Clear patent map; 2. Risk‑sharing agreements. |
| Reimbursement & policy changes | Payers may introduce new cost‑effectiveness thresholds or value‑based contracts. | A new policy in 2028/2029 could make reimbursement more restrictive for biosimilars. | 1. Early negotiation with payers.
2. Collect health‑economic data. |
| Supply chain & manufacturing capacity | Biosimilars require large bioreactors; shortages of raw materials can delay production. | The risk of production bottlenecks is moderate. | 1. Diversify suppliers.
2. Maintain excess capacity. |
---
Bottom‑line Take‑aways for 2029
1. Timing – A first‑to‑market biosimilar for Dupixent is plausible in 2029, but regulatory, patent, and manufacturing hurdles could push the launch to 2030 or later.
2. Risk Level – Most risks are moderate (e.g., patent litigation, market penetration) and can be managed with proactive strategies.
3. Mitigation – Early engagement with regulators, clear patent mapping, robust clinical and real‑world data, and strong payer negotiations are critical.
4. Strategic Opportunity – For the originator, a phased “exclusivity extension” strategy (e.g., new indications, delivery devices) can sustain value past 2029. For the biosimilar, a differentiated launch strategy (e.g., value‑based contracts, patient support) can capture market share.
---
Key Resources (for deeper dives)
- FDA’s “Guidance for Industry: Biosimilars” (latest 2024 revision).
- EMA’s “Guidelines on the quality, non‑clinical and clinical aspects of biopharmaceuticals for the approval of biosimilar medicines.”
- Dupixent (dupilumab) product label (2026) – note any emerging safety signals.
---
Feel free to let me know if you’d like more detail on any specific aspect (e.g., clinical trial design for a biosimilar, reimbursement models, or real‑world evidence collection).